Qualigen Therapeutics (NASDAQ:QLGN) Shares Set to Reverse Split on Tuesday, November 5th

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares are scheduled to reverse split on Tuesday, November 5th. The 1-50 reverse split was announced on Friday, November 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 4th.

Qualigen Therapeutics Price Performance

Qualigen Therapeutics stock remained flat at $0.10 during midday trading on Friday. 2,658,167 shares of the company traded hands, compared to its average volume of 4,660,945. The company has a 50-day simple moving average of $0.16 and a 200 day simple moving average of $0.22. Qualigen Therapeutics has a 12-month low of $0.08 and a 12-month high of $0.78.

Qualigen Therapeutics (NASDAQ:QLGN) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.